Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trial

Kevin D. Costa,Andy O.T. Wong,Suet Yee Mak,Erin G. Roberts,Wendy Keung,Claudia Correia,Anna Walentinsson,Jonas Christoffersson,Alice Cheung,Deborah K. Lieu,Karin Jennbacken,Qing-Dong Wang,Roger J. Hajjar,Ronald A. Li

DOI: https://doi.org/10.1101/2024.08.27.609034

2024-08-28

Abstract:Aims: Heart failure with preserved ejection fraction (HFpEF), is a global health problem lacking disease-modifying therapeutic options, reflecting a lack of predictive models for preclinical drug testing. Aligned with FDA Modernization Act 2.0, we aimed to create the first in vitro human-specific mini-heart models of HFpEF, and to test the efficacy of a candidate gene therapy to improve cardiac kinetics and correct the disease phenotype. Methods and Results: Healthy human pluripotent stem cell-derived ventricular cardiomyocytes were used to bioengineer beating cardiac tissue strips and pumping cardiac chambers. When conditioned with transforming growth factor-β1 and endothelin-1, these mini-heart models exhibited signature disease phenotypes of significantly elevated diastolic force and tissue stiffness, and slowed contraction and relaxation kinetics, with no significant deficit in systolic force or ejection fraction versus unconditioned controls. Bioinformatic analysis of bulk RNA sequencing data from HFpEF mini-heart models and patient ventricular samples identified downregulation of SERCA2a of the calcium signalling pathway as a key differentially expressed gene. After dosage optimization, AAV-mediated expression of SERCA2a abrogated the disease phenotype and improved the cardiac kinetics in HFpEF mini-Hearts. Conclusions: These findings contributed to FDA approval of an ongoing first-in-human gene therapy clinical trial for HFpEF, with Fast Track designation. We conclude that such human-based disease-specific mini-heart platforms are relevant for target discovery and validation that can facilitate clinical translation of novel cardiac therapies.

Bioengineering

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the lack of effective disease - modifying treatment methods for Heart Failure with Preserved Ejection Fraction (HFpEF). HFpEF is a global health problem, and currently there is a lack of effective pre - clinical drug - testing models, resulting in limited treatment options. The main goal of the paper is to create the first in - vitro human - specific small - scale heart model to simulate HFpEF and test the effectiveness of a candidate gene therapy to improve cardiac dynamics and correct the disease phenotype.

Specifically, the research team used healthy human pluripotent stem - cell - derived ventricular cardiomyocytes to construct beating heart tissue strips and pumping heart chambers. By treating these small - scale heart models with conditioned media (such as Transforming Growth Factor - β1 and Endothelin - 1), they exhibited significantly increased diastolic force and tissue stiffness, as well as slowed contraction and relaxation dynamics, but without an obvious decrease in contractile force or ejection fraction. Through bioinformatics analysis, the study found that the down - regulation of the SERCA2a gene in the calcium signaling pathway is a key differentially expressed gene. Further research indicates that AAV - mediated SERCA2a expression can reverse the disease phenotype and improve cardiac dynamics.

These findings have contributed to the FDA's approval of an ongoing first - in - human gene - therapy clinical trial for HFpEF and have obtained the Fast - Track designation. The research results show that the human - based small - scale heart platform for specific diseases is of great significance for target discovery and validation and can promote the clinical translation of new cardiac therapies.